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Abstract
Despite endophthalmitis being the most feared complication, antibioprophylaxis remains
controversial in intravitreal injections. Therefore, we conducted a systematic review and
meta-analysis on the effects of antibioprophylaxis in intravitreal injections in the prevention
of endophthalmitis. The PubMed, Cochrane Library, Embase and Science Direct databases
were searched for studies comparing groups with and without antibiotics in intravitreal injec-
tion, with the use of the following keywords: "antibiotic*", "endophthalmitis" and “intravitreal
injection*”. To be included, studies needed to specify number of participants and number of
endophthalmitis within each group (with and without antibiotics). We conducted meta-analy-
sis on the prevalence of clinical endophthalmitis including both culture-proven and culture
negative samples. Nine studies were included. A total of 88 incidences of endophthalmitis
were reported from 174,159 injections (0.051% i.e., one incidence of endophthalmitis for
1979 injections). Specifically, 59 incidences of endophthalmitis were reported from 113,530
injections in the group with antibiotics (0.052% or one incidence of endophthalmitis for 1924
injections) and 29 incidences of endophthalmitis from 60,633 injections in the group without
antibiotics (0.048% or one endophthalmitis for 2091 injections). Our meta-analysis did not
report a significant difference in the prevalence of clinical endophthalimitis between the two
groups with and without topical antibiotics: the odds ratio of clinical endophthalimitis was
0.804 (CI95% 0.384–1.682, p = 0.56) for the antibiotic group compared with the group with-
out antibiotics. In conclusion, we performed the first large meta-analysis demonstrating that
antibioprophylaxis is not required in intravitreal injections. Strict rules of asepsis remain the
only evidence-based prophylaxis of endophthalmitis. The results support initiatives to
reduce the global threat of resistance to antibiotics.
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Introduction
Anti-VEGF intravitreal injections have demonstrated a relative efficacy to treat common diseases
such as wet age-related macular degeneration, diabetic macular edema and central and branch
retinal vein occlusion [1]. Therefore, intravitreal injections are a commonmedical procedure,
performed annually by millions across industrialized countries [2]. Transfixing perforation of the
sclera of the eye by the injection needle might lead to infectious complications, specifically
endophthalmitis [3]. Although rare [4,5,6,7], endophthalmitis is the most feared complication of
intravitreal injections due to its poor functional prognosis [8]. Strategies for infection prophylaxis
are generally based on the use of antiseptics and antibiotics. Regarding antiseptics, the use of
povidone-iodine to the ocular surface along with aseptic techniques in anterior segment surgery
have been the only type of intervention shown to be moderately important in reducing the risk of
post-operative endophthalmitis [9]. However, the use of antibiotics remains under debate.
Despite the absence of evidence-based data, the common clinical practice involved topical antibi-
otics before, concurrently with, or after the intravitreal injection [10]. The usefulness of antibiot-
ics in the prevention of endophthalmitis after intravitreal injections has been more recently
questioned. No prospective randomized study demonstrated the benefits of topical antibiotics.
Additionally, topical antibiotics enhanced rapid development of antibiotic-resistant virulent bac-
teria on the ocular surface and spreading in the oral sphere [11,12].
Despite the absence of data to support the reduction of endophthalmitis through the use of
antibiotics after intravitreal injection, many ophthalmologists continue to recommend a multiday
course of topical antibiotic use after intravitreal injection. Therefore, because antibiotics can be
unecessary and detrimental [13], we aimed to conduct a systematic review and meta-analysis on
putative benefits of antibiotic prophylaxis in preventing endophthalmitis after intravitreal injec-
tions, and to strengthen the evidence base for establishing international guidelines.
Methods
Literature Search
We reviewed all cohort studies found on Medline via Pubmed that compared two groups after
intravitreal injections: one with antibiotics and one without. Keywords for the search strategy
were "antibiotic", "endophthalmitis" and “intravitreal injection”. The following databases
were searched on December 23rd, 2015: PubMed, Cochrane Library, Science Direct and
Embase. The search was not limited to specific years and no language restrictions applied. To
be included, studies needed to specify the number of participants and quantify the incidence of
endophthalmitis within each group (with and without antibiotics). All kinds of intravitreal
injections were included i.e. corticoids (triamcinolone, dexamethasone) or anti-VEGF such as
monoclonal antibodies (mab–bevacizumab, ranibizumab), recombinant proteins (aflibercept)
and pegatnamib. In addition, reference lists of all publications meeting the inclusion criteria
were manually searched to identify any further studies not identified via electronic searching.
The search strategy is described in Fig 1. One author (CBA) conducted all literature searches
and collated the abstracts. Two authors (CBA and FD) separately reviewed the abstracts and
based on the selection criteria, decided the suitability of the articles for inclusion. A third
author (GN) was asked to review the article where consensus on suitability was not met. Then,
all authors reviewed the eligible articles.
Quality of assessment
Although not designed for quantifying the integrity of studies [14], the “STrengthening the
Reporting of OBservational studies in Epidemiology” (STROBE) criteria were used for
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checking the quality of reporting [15]. The 22 items identified in the STROBE criteria could
gain achieve a maximal score of 33.
Statistical considerations
Statistical analysis was conducted using Comprehensive Meta-analysis software (version 2, Biostat
Corporation) and Stata software (version 13, StataCorp, College Station, US). Extracted data were
summarized for each study and reported as mean (standard-deviation) and number (%) for con-
tinuous and categorical variables respectively. Prevalence of endophthalmitis and 95% confidence
intervals were estimated using random-effects models assuming between and within study vari-
ability (DerSimonian and Laird approach). Statistical heterogeneity between results was assessed
using forest plots, confidence intervals and I². The I2 statistic is the most commonmetric for mea-
suring the magnitude of between-study heterogeneity and is easily interpretable. I² values range
between 0 and 100% and are typically considered low for values<25%, modest for 25–50%, and
high for>50%. This statistical method generally assumes heterogeneity when the p-value of the I²
Fig 1. Search strategy.
doi:10.1371/journal.pone.0156431.g001
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test is<0.05. A sensitivity analysis was thus conducted to assess the influence on the global preva-
lence of the inclusion and exclusion of studies. Then, we conducted a meta-analysis on the preva-
lence of clinical endophthalmitis including both culture-proven and culture negative samples and
where possible (sufficient sample size), on the prevalence of endophthalmitis depending on the
type of products used for intravitreal injections (taking into account antibiotics prescription), and
on the type of germs identified if the culture was positive. We also aimed to propose meta-regres-
sions too investigate relations between the prevalence and clinically relevant parameters according
to the literature. Results were expressed as regression coefficients and 95% confidence intervals.
Type I-error was fixed at a = 0.05.
Results
An initial search produced a possible for 943 articles. Removal of duplicates and selection crite-
ria reduced the articles comparing two groups to nine articles (Fig 1 and Table 1).
Quality of articles
Quality assessment of the nine included studies was analyzed by the STROBE criteria, from
which results varied from 57.6 to 94.0%, with a mean score of 77.1±13.7%. Overall, the studies
performed best in the discussion section and worst in the methods section.
Population
Sample size. Only two studies reported the number of patients i.e. 4767 [16] and 1185 par-
ticipants [17]. All studies reported the total number of injections ranging from 620 [18] to
Table 1. Repartition of culture in the 2 groups in each study and prevalence of endophthalmitis in each study.
Study Total Group with antibiotic Group without antibiotic
Number of
endophthalmitis /
Number of
injections
Culture
(+)
Culture
(-)
Number of
endophthalmitis /
Number of
injections
Culture
(+)
Culture
(-)
Number of
endophthalmitis /
Number of
injections
Culture
(+)
Culture
(-)
Bhatt et al, 2011 10/4767 1 9 5/2287 0 5 5/2480 1 4
Bhavsar et al,
2012
7/8027 5 2 6/4697 4 2 1/3333 1 0
Cheung et al,
2012
9/15895 3 6 7/10629 1 6 2/5266 2 0
Meredith et al,
2015*
11/18509 7 3 8/16509 6 1 3/2000 1 2
Pachuo et al,
2015
0/620 0 0 0/310 0 0 0/310 0 0
Park et al, 2013 3/17332 1 2 0/8649 0 0 3/8683 1 2
Ramel et al, 2014 6/11450 5 1 3/10144 2 1 3/1306 3 0
Storey et al,
2014**
39/92554 14 25 28/57654 10 18 11/34900 4 7
Stranak et al,
2014
3/5005 1 2 2/2651 0 2 1/2355 1 0
Total
Number 88/174159 37 50 59/113530 26 35 29/60633 14 15
Prevalence (%) 0.021 0.029 0.020 0.031 0.023 0.018
* 1 endophthalmitis had not culture results
** Transition period with unknown antibiotic prescription was excluded
doi:10.1371/journal.pone.0156431.t001
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92,554 [19]. Overall, our current meta-analyses included a total of 174,159 injections: 113,530
with antibiotics and 60,633 without antibiotics (Table 1).
Age. Only two studies reported the median age within patients; specifically 72.2 [13] and
79.3 [20] years old. A third study reported an age of the population ranging from 30 to 70 years
old, but did not specify a mean or median age [18]. Other studies did not provide any informa-
tion on the age of patients.
Gender. Gender was not specified in all of the nine retrieved studies.
Intravitreal injections
Indications for injections. Four studies provided details of the indications for injections
which were exudative age-related macular degeneration [13,17,18], choroidal neovascular
membranes secondary to myopic degeneration [13,18], macular edema secondary to diabetes
[13,18,21], central and branch retinal vein occlusions [13,18], uveitis [13,18], birdshot chorior-
etinopathy [13] and other proliferative retinopathies [13]. The five other studies included all
patients needing intravitreal injections but did not specify more detailed indications
[16,19,20,22,23].
Type of products injected. all studies reported injections of bevacizumab except one [21],
all studies reported injections of ranibizumab except one [18], six studies used triamcinolone
injections [13,16,20,21,22,23], three studies reported pegatnamib injections [13,20,23], one
gave aflibercept [19], one reported dexamethasone injections [23] and one reported a C3F8
injection [22]. Among the studies reporting multiple products within the injection, five com-
bined injections of bevacizumab, ranibizumab and triamcinolone [13,16,20,22,23], three com-
bined bevacizumab, ranibizumab, triamcinolone and pegatnamib [13,20,23], one reported
simultaneously ranibizumab and triamcinolone [21], and one bevacizumab and ranibizumab
[19]. However, only one of these studies reported the sample size with and without antibiotics
within each group of type of products injected [19]. Subsequently, more advanced meta-analy-
ses were unable to be conducted.
Antibiotics use
All included articles reported only topical antibiotics, with the exception of one study which
also administrated one oral dose of antibiotic post injection (ciprofloxacin 500 mg) during
three days in addition to topical antibiotics [18]. One study prescribed topical antibiotics only
for the three days preceding the intravitreal injection [22]. Another study used a topical antibi-
otic before and after the injection (levofloxacin 5 times daily the 3 days before and the 3 days
after injection) [23]. Four studies administered antibiotics during and after the injection (one
drop immediately at the end of procedure and then a 4th generation fluoroquinolone after 3 or
5 days [13,16] or tobramycin 4 times daily during 4 days [20] or azithromycin twice daily dur-
ing 3 days [20] or others left the prescription of topical antibiotics to the discretion of individ-
ual physicians). Finally, one article reported antibiotics only after the injection (4 times daily
during 4 days) [19]. Two articles left the prescription of topical antibiotics to the discretion of
physicians, and thus did not specify whether antibiotics were administered before, during
or after intravitreal injection [17,21]. One study reported a transition period in which the anti-
biotic prescription was unknown; excluding this transition period from our meta-analyses
[19].
Bacteriology
Staphylococcus and streptococcus are the most frequent germs found in culture-proven
endophthalmitis (47.5% and 35%, respectively) (Table 2). Enterococcus was found within two
Antibioprophylaxis in Intravitreal Injections
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studies [13,19], and only one lactobacillus was found out of 37 culure-proven endophthalmitis
[19].
Outcomes and aims of the studies
The primary outcome was the incidence of endophthalmitis between two groups: one with
antibiotics and one without. Secondary outcomes were clearly defined in two studies and
involved investigations of the microbial spectrum [13,17,19] and clinical outcomes including
return to baseline visual acuity [17,19]. However, other studies also described microbial spec-
trum [16,18,20,21,22,23] and four studies reported the number of endophthalmitis for each
product used [13,19,22,23]. However, whether it was in group with or without antibiotics was
unclear.
Study designs
Six studies were retrospective [13,16,19,20,22,23] and three were prospective [17,18,21]. All
studies were published after 2011; with the duration of follow-up ranging from 12 [18] to 108
months [21].
Meta-analysis on prevalence of clinical endopthalmitis
A total of 88 incidences of endophthalmitis were reported from the 174,159 injections (0.051%
or one incidence of endophthalmitis from 1979 injections), ranging from 0/620 (0%) [18] to 1/
477 (0.21%) [16]. Specifically, 59 endophthalmitis were reported from 113,530 injections in the
group with antibiotics (0.052% or one incidence of endophthalmitis from 1924 injections) and
29 endophthalmitis from 60,633 injections in the group without antibiotics (0.048% or one
incidence of endophthalmitis from 2091 injections) (Table 1). Our meta-analysis did not report
a significant difference in the prevalence of clinical endophthalimitis between the two groups
with and without topical antibiotics: the odds ratio of clinical endophthalimitis was 0.804
(CI95% 0.384–1.682, p = 0.56) for the antibiotics group compared with the group without anti-
biotics, with moderate heterogeneity between studies (I-squared = 47.2%, p = .056) (Fig 2).
Meta-analysis on prevalence of culture-proven endopthalmitis
When considering only culture-proven endophthalmitis, a total of 37 incidences of culture-
proven endophthalmitis were reported from 174,159 injections (0.021% or one incidence of
endophthalmitis from 4,707 injections) and thus, a total of 50 culture-negative cases of sus-
pected endophthalmitis were reported from 174,159 injections (0.029% or one incidence of
endophthalmitis from 3,483 injections) (one described case of endophthalmitis lacked culture
results) (Table 1) [17]. Specifically, 23 culture-proven endophthalmitis were reported from
113,530 injections in the group with antibiotics (0.020% or one incidence of endophthalmitis
from 4,936 injections) and 14 incidences of culture-proven endophthalmitis from 60,633
injections in the group without antibiotics (0.023% ior one incidence of endophthalmitis from
4,331 injections). Including only culture-negative cases, 35 culture-negative incidences of
endophthalmitis were reported from 113,530 injections in the group with antibiotics (0.031%
or one incidence of endophthalmitis from 3,244 injections) and 15 incidences of culture-
proven endophthalmitis from 60,633 injections in the group without antibiotics (0.025% or
one incidence of endophthalmitis from 4,042 injections). Our meta-analysis did not report a
significant difference in the incidence of culture-proven endophthalimitis between the 2 groups
with and without topical antibiotics: the odd ratio of culture-proven endophthalimitis was
Antibioprophylaxis in Intravitreal Injections
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0.552 (CI 95% 0.240–1.265, p = 0.160) for the antibiotics group compared with the group with-
out antibiotics; with low heterogeneity between studies (I-squared = 20.1%, p = 0.177) (Fig 3).
Other meta-analyses and meta-regressions
An insufficient number of studies reported the specific types of antibiotics used and types of
products injected (bevacizumab, ranibizumab, triamcinolone). Therefore, low numbers of
studies precluded meta-analyses on the influence of types of products injected to reduce the
risk of endophthalmitis. Insufficient sample sizes also precluded meta-analyses on bacteries
retrieved in culture proven endophthalmitis. Similarly, only two studies reported the number
of patients, only two studies reported age, and no studies reported gender (S1 Database). Con-
sequently, no meta-regressions were conducted.
Discussion
This current study is the first large meta-analysis on the effectiveness of antibioprophylaxis in
the prevention of endophthalmitis via intravitreal injection. We included a total of 174,159
injections, with a 0.052% or one incidence of endophthalmitis from 1924 injections) in the
group with antibiotics and 0.048% or one incidence of endophthalmitis from 2091 injections in
Fig 2. Odd ratio for each study including both culture-proven and culture negative endophthalmitis.
doi:10.1371/journal.pone.0156431.g002
Fig 3. Odd ratio for each study including only culture-proven endophthalmitis.
doi:10.1371/journal.pone.0156431.g003
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the group without antibiotics. The major finding ere was the absence of difference in the inci-
dence of endophthalmitis with and without antibioprophylaxis (OR = 0.804, CI95% 0.384–
1.682, p = 0.56) for the antibiotic group compared with the group without antibiotics; with a
moderate heterogeneity between studies (I-squared = 47.2%, p = .056).
The threat of antibiotics
Repeated use of antiobioprophylaxis, such as in monthly intravitreal injections, promote resis-
tance [11] and virulence [24] of the conjunctival flora, even on short durations with low doses
[24]. The minimum inhibitory concentration of antibiotics at the conjunctival flora increased
in patients receiving antibiotics after the third injection [11]. Moreover, topical antibiotics and
povidone–iodine before intravitreal injections did not further reduce bacterial concentrations
compared with povidone–iodine alone [25]. Therefore, some authors calculated the sample
size required to perform a non-inferiority test of antiseptics compared with antibiotics, ranged
from 25,000 [13] to 50,000 [20] injections per group. In addition, a single application of povi-
done–iodine demonstrated a bactericidal effect equivalent to a 3-day course of topical antibiot-
ics [26]. Also, repeated topical antibiotics applications may cause resistance in the
nasopharynx [27]. Pharmacologically, intravitreal penetration of topical antibiotic is below the
minimum inhibitory concentration required for a therapeutic effect [28]. Finally, systematic
use of topical antibiotics generates a substantial cost, both for patients and society. The evi-
dence-based strategy for preventing endophthalmitis remains the use of an eyelid speculum,
povidone-iodine, surgical mask and sterile gloves [29].
Promoting guideline for antibioprophy
This is the first large meta-analysis demonstrating the absence of systematic antibioprophylaxis
in prevention of endophthalmitis in intravitreal injections. The moderate heterogeneity
reported in our study is due to the low incidence of endophthalmitis; ranging from 0 [18] to
0.21% [16]. Even if the study of Dorssaps et al (2015) could not have been included in our
meta-analyses because it did not report numbers of endophthalmitis and total number of intra-
vitreal injections within a group with and without antibiotics, authors reported that the use of
an antibiotic or antiseptic increased the incidence of endophthalmitis (relative risk = 2.77,
CI95% 1.54–5.00, p = .001) [4]. Moreover, we must acknowledge that the study of Dorssaps
et al (2015) was conducted over 25 centers and included more than 300,000 intravitreal injec-
tions [4]. Therefore, despite the absence of guidelines regarding use the antibiotics in intravi-
treal injections, some ophthalmologists recently stopped antibioprophylaxis. Also some
ophthalmologists reported a low incidence of endophthalmitis can be achieved in the absence
of topical antibiotics [30]. Moreover, one of the lowest incidences of endophthalmitis in the lit-
erature was reported in this study that included a large sample size of intravitreal injections
without antibiotics; resulting in only one incidence of endophthalmitis from 18,839 injections
(0.0053%) [30].
Limitations
All meta-analyses have limitations [31]. Meta-analyses inherit the limitations of the individual
studies of which they are composed. The low number of prospective studies reported the lowest
number of injections. Antibiotic treatment protocols differed between selected studies and
insufficient data precluded further analyses on protocols used. The incidence of culture-nega-
tive endophthalmitis may seem high however, it is similar to literature (0.022%) [5]. Even if
non-significant, the culture-proven endophthalimitis odds ratio of 0.552 (CI 95% 0.240–1.265,
p = 0.160) for the antibiotics group compared with the group without antibiotics may limit
Antibioprophylaxis in Intravitreal Injections
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generalizability. However, in real practice, all endophthalmitis generate an undesirable progno-
sis (including culture negative endophthalmitis) [19]. A large multicenter prospective cluster
randomized controlled trial, with consistent protocols, would help promote international
guidelines; nonetheless the sample size required would make this study problematic to manage.
Preliminary plans to target sub-group analyses for types of antibiotic used, products injected,
and the bacteria retrieved in culture-proven endophthalmitis, were not feasible due to insuffi-
cient numbers of studies with these details.
Conclusion
We performed the first large meta-analysis demonstrating that antibioprophylaxis treatment is
not required in intravitreal injections. Strict rules of asepsis remain the only evidence-based
support for prophylaxis of endophthalmitis. The results support initiatives to reduce the global
threat of resistance to antibiotics. Therefore, antibiotics should be prescribed only in excep-
tional cases such as immunosuppression or fragile conjunctiva. International guidelines sur-
rounding the use of antibiotics in intravitreal injections should be generated.
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